AstraZeneca says COVID-19 vaccine effective against Delta variant
AstraZeneca PLC (LON:AZN) said its Coronavirus (COVID-19) vaccine developed with Oxford University is effective against the Delta and Kappa variant, which were first found in India.
The FTSE 100 cited a study by the university built on an analysis by the Public Health England (PHE), Reuters reported.
Last week, PHE said a full course of the AstraZeneca jab is 92% effective against hospitalisation from the strain, while the Pfizer/BioNTech vaccine offers 96% protection.
Researchers are still investigating their efficacy against death, although it is “expected to be high”, PHE said.
The analysis included 14,019 cases of the Delta variant – 166 of whom were hospitalised – between 12 April and 4 June, looking at emergency hospital admissions in England.
As of last week, the Delta variant accounted for 99% of cases in the UK, which had risen by 33,630 in a week to a total of 75,953.